The effects of preoperative chemoradiotherapy on lymph node sampling in rectal Cancer

Eric D. Miller, Bruce Robb, Oscar Cummings, Peter A S Johnstone

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

BACKGROUND: The current recommendation from the American Joint Committee on Cancer and the International Union Against Cancer is that 12 or more lymph nodes should be examined to appropriately stage rectal cancer. It is unclear if this metric is appropriate or achievable for patients who receive neoadjuvant therapy. OBJECTIVE: The purpose of this study was to review the effects of neoadjuvant chemoradiotherapy on the lymph node yield in patients with rectal cancer. DATA SOURCES: A comprehensive search was made of MEDLINE, PubMed, and Web of Science for articles published through December 2011. STUDY SELECTION: The descriptors rectal neoplasms, lymph nodes, lymph node yield, radiotherapy, and neoadjuvant therapy were used to identify articles that reported the lymph node yield with and without neoadjuvant chemoradiotherapy for rectal cancer. INTERVENTIONS: Patients received either chemoradiotherapy or no neoadjuvant treatment before undergoing total mesorectal excision for rectal cancer. MAIN OUTCOME MEASURES: The main outcome measures included the mean lymph node yield both with and without neoadjuvant treatment, the percentage of patients that received an adequate lymph node dissection, and the number of lymph nodes found to be positive for metastatic disease. RESULTS: A total of 7 studies were included in this review. They demonstrated a decrease in lymph node yield in patients who received neoadjuvant therapy, ranging from 7% to 53% based on the articles in this review. LIMITATIONS: A meta-analysis was not performed because of the limited complete data published on this subject. Consequently, there is heterogeneity in the studies that were selected for this review. CONCLUSIONS: Patients with rectal cancer who receive preoperative chemoradiotherapy should be anticipated to have a lower lymph node yield than patients who receive surgery alone. This calls into question if the current guideline of 12 lymph nodes is relevant, in particular, for those patients receiving neoadjuvant therapy.

Original languageEnglish
Pages (from-to)1002-1007
Number of pages6
JournalDiseases of the Colon and Rectum
Volume55
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Chemoradiotherapy
Rectal Neoplasms
Lymph Nodes
Neoadjuvant Therapy
Lymph Node Excision
PubMed
MEDLINE
Meta-Analysis
Radiotherapy
Outcome Assessment (Health Care)
Guidelines

Keywords

  • Lymph node yield
  • Neoadjuvant treatment
  • Rectal neoplasms

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The effects of preoperative chemoradiotherapy on lymph node sampling in rectal Cancer. / Miller, Eric D.; Robb, Bruce; Cummings, Oscar; Johnstone, Peter A S.

In: Diseases of the Colon and Rectum, Vol. 55, No. 9, 09.2012, p. 1002-1007.

Research output: Contribution to journalArticle

@article{20c7d6352d694554b2c1594f10cb136a,
title = "The effects of preoperative chemoradiotherapy on lymph node sampling in rectal Cancer",
abstract = "BACKGROUND: The current recommendation from the American Joint Committee on Cancer and the International Union Against Cancer is that 12 or more lymph nodes should be examined to appropriately stage rectal cancer. It is unclear if this metric is appropriate or achievable for patients who receive neoadjuvant therapy. OBJECTIVE: The purpose of this study was to review the effects of neoadjuvant chemoradiotherapy on the lymph node yield in patients with rectal cancer. DATA SOURCES: A comprehensive search was made of MEDLINE, PubMed, and Web of Science for articles published through December 2011. STUDY SELECTION: The descriptors rectal neoplasms, lymph nodes, lymph node yield, radiotherapy, and neoadjuvant therapy were used to identify articles that reported the lymph node yield with and without neoadjuvant chemoradiotherapy for rectal cancer. INTERVENTIONS: Patients received either chemoradiotherapy or no neoadjuvant treatment before undergoing total mesorectal excision for rectal cancer. MAIN OUTCOME MEASURES: The main outcome measures included the mean lymph node yield both with and without neoadjuvant treatment, the percentage of patients that received an adequate lymph node dissection, and the number of lymph nodes found to be positive for metastatic disease. RESULTS: A total of 7 studies were included in this review. They demonstrated a decrease in lymph node yield in patients who received neoadjuvant therapy, ranging from 7{\%} to 53{\%} based on the articles in this review. LIMITATIONS: A meta-analysis was not performed because of the limited complete data published on this subject. Consequently, there is heterogeneity in the studies that were selected for this review. CONCLUSIONS: Patients with rectal cancer who receive preoperative chemoradiotherapy should be anticipated to have a lower lymph node yield than patients who receive surgery alone. This calls into question if the current guideline of 12 lymph nodes is relevant, in particular, for those patients receiving neoadjuvant therapy.",
keywords = "Lymph node yield, Neoadjuvant treatment, Rectal neoplasms",
author = "Miller, {Eric D.} and Bruce Robb and Oscar Cummings and Johnstone, {Peter A S}",
year = "2012",
month = "9",
doi = "10.1097/DCR.0b013e3182536d70",
language = "English",
volume = "55",
pages = "1002--1007",
journal = "Diseases of the Colon and Rectum",
issn = "0012-3706",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - The effects of preoperative chemoradiotherapy on lymph node sampling in rectal Cancer

AU - Miller, Eric D.

AU - Robb, Bruce

AU - Cummings, Oscar

AU - Johnstone, Peter A S

PY - 2012/9

Y1 - 2012/9

N2 - BACKGROUND: The current recommendation from the American Joint Committee on Cancer and the International Union Against Cancer is that 12 or more lymph nodes should be examined to appropriately stage rectal cancer. It is unclear if this metric is appropriate or achievable for patients who receive neoadjuvant therapy. OBJECTIVE: The purpose of this study was to review the effects of neoadjuvant chemoradiotherapy on the lymph node yield in patients with rectal cancer. DATA SOURCES: A comprehensive search was made of MEDLINE, PubMed, and Web of Science for articles published through December 2011. STUDY SELECTION: The descriptors rectal neoplasms, lymph nodes, lymph node yield, radiotherapy, and neoadjuvant therapy were used to identify articles that reported the lymph node yield with and without neoadjuvant chemoradiotherapy for rectal cancer. INTERVENTIONS: Patients received either chemoradiotherapy or no neoadjuvant treatment before undergoing total mesorectal excision for rectal cancer. MAIN OUTCOME MEASURES: The main outcome measures included the mean lymph node yield both with and without neoadjuvant treatment, the percentage of patients that received an adequate lymph node dissection, and the number of lymph nodes found to be positive for metastatic disease. RESULTS: A total of 7 studies were included in this review. They demonstrated a decrease in lymph node yield in patients who received neoadjuvant therapy, ranging from 7% to 53% based on the articles in this review. LIMITATIONS: A meta-analysis was not performed because of the limited complete data published on this subject. Consequently, there is heterogeneity in the studies that were selected for this review. CONCLUSIONS: Patients with rectal cancer who receive preoperative chemoradiotherapy should be anticipated to have a lower lymph node yield than patients who receive surgery alone. This calls into question if the current guideline of 12 lymph nodes is relevant, in particular, for those patients receiving neoadjuvant therapy.

AB - BACKGROUND: The current recommendation from the American Joint Committee on Cancer and the International Union Against Cancer is that 12 or more lymph nodes should be examined to appropriately stage rectal cancer. It is unclear if this metric is appropriate or achievable for patients who receive neoadjuvant therapy. OBJECTIVE: The purpose of this study was to review the effects of neoadjuvant chemoradiotherapy on the lymph node yield in patients with rectal cancer. DATA SOURCES: A comprehensive search was made of MEDLINE, PubMed, and Web of Science for articles published through December 2011. STUDY SELECTION: The descriptors rectal neoplasms, lymph nodes, lymph node yield, radiotherapy, and neoadjuvant therapy were used to identify articles that reported the lymph node yield with and without neoadjuvant chemoradiotherapy for rectal cancer. INTERVENTIONS: Patients received either chemoradiotherapy or no neoadjuvant treatment before undergoing total mesorectal excision for rectal cancer. MAIN OUTCOME MEASURES: The main outcome measures included the mean lymph node yield both with and without neoadjuvant treatment, the percentage of patients that received an adequate lymph node dissection, and the number of lymph nodes found to be positive for metastatic disease. RESULTS: A total of 7 studies were included in this review. They demonstrated a decrease in lymph node yield in patients who received neoadjuvant therapy, ranging from 7% to 53% based on the articles in this review. LIMITATIONS: A meta-analysis was not performed because of the limited complete data published on this subject. Consequently, there is heterogeneity in the studies that were selected for this review. CONCLUSIONS: Patients with rectal cancer who receive preoperative chemoradiotherapy should be anticipated to have a lower lymph node yield than patients who receive surgery alone. This calls into question if the current guideline of 12 lymph nodes is relevant, in particular, for those patients receiving neoadjuvant therapy.

KW - Lymph node yield

KW - Neoadjuvant treatment

KW - Rectal neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84866040221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866040221&partnerID=8YFLogxK

U2 - 10.1097/DCR.0b013e3182536d70

DO - 10.1097/DCR.0b013e3182536d70

M3 - Article

C2 - 22874609

AN - SCOPUS:84866040221

VL - 55

SP - 1002

EP - 1007

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

SN - 0012-3706

IS - 9

ER -